One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
Evaluate the Safety and Efficacy of JCXH-213 in Patients with Relapsed/Refractory B-cell non-Hodgkin Lymphoma
B-Cell Non-Hodgkin Lymphoma-Recurrent|B-Cell Non-Hodgkin Lymphoma-Refractory
DRUG: JCXH-213,an mRNA-LNP based in vivo CAR therapy
Dose limiting toxicity (DLT)., The DLT observation period is 21 days after first infusion of JCXH-213.
Patient will receive study treatment in the treatment observation period. After the end of the treatment observation period, patients will be allowed to continue to receive treatment if there is no major safety problems and the investigator judges that the patient may continue to benefit.